AllianceBernstein Portfolio holdings
AllianceBernstein (AB), formed in 2000 through the merger of Alliance Capital and Bernstein, is a global asset management firm headquartered in Nashville, Tennessee, managing over $759 billion in assets as of late 2024 for institutional investors, financial advisors, and individuals. Known for its research-driven approach, AB offers a diverse range of investment strategies, including equities, fixed income, alternatives, and multi-asset solutions, with a strong emphasis on active management and ESG (environmental, social, governance) integration. The firm, which relocated its headquarters from New York City to Nashville in 2021, operates globally with significant operations in New York, London, and Asia, leveraging its Bernstein Research arm for deep market insights. With a workforce of over 4,700 and a partnership structure led by CEO Seth Bernstein, AB combines a legacy of rigorous analysis with a modern focus on sustainable investing and client outcomes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$567M |
| 2 |
Visa
V
|
+$283M |
| 3 |
CVS Health
CVS
|
+$195M |
| 4 |
Texas Instruments
TXN
|
+$188M |
| 5 |
Progressive
PGR
|
+$187M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$274M |
| 2 |
Microsoft
MSFT
|
+$263M |
| 3 |
Comcast
CMCSA
|
+$248M |
| 4 |
Amphenol
APH
|
+$238M |
| 5 |
Elevance Health
ELV
|
+$238M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.59% |
| 2 | Financials | 14.66% |
| 3 | Healthcare | 14.25% |
| 4 | Consumer Discretionary | 10.15% |
| 5 | Industrials | 10.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LORL
2301
DELISTED
Loral Space and Communications, Inc.
LORL
| $833K | ﹤0.01% |
21,305
-650
| -3% | -$23.5K |
|
2302
Encore Capital Group
ECPG
$1.93B
| $832K | ﹤0.01% |
37,019
-2,400
| -6% | -$54.1K |
|
2303
Dillards
DDS
$8.87B
| $828K | ﹤0.01% |
13,146
-200
| -1% | -$12.5K |
|
2304
Minerva Neurosciences
NERV
$188M
| $826K | ﹤0.01% |
7,313
| – | – |
|
|
ORBC
2305
DELISTED
ORBCOMM, Inc.
ORBC
| $822K | ﹤0.01% |
80,200
| – | – |
|
2306
Bausch Health
BHC
$1.65B
| $820K | ﹤0.01% |
33,389
+2,561
| +8% | +$66.3K |
|
2307
Douglas Dynamics
PLOW
$1.07B
| $818K | ﹤0.01% |
25,620
+1,200
| +5% | +$35.9K |
|
2308
Unitil
UTL
$1,000M
| $816K | ﹤0.01% |
20,900
-23,130
| -53% | -$954K |
|
2309
Iridium Communications
IRDM
$4.85B
| $815K | ﹤0.01% |
100,540
-5,700
| -5% | -$47.8K |
|
2310
Globalstar
GSAT
$10.2B
| $814K | ﹤0.01% |
44,847
+1,160
| +3% | +$21.9K |
|
|
LNW
2311
DELISTED
Light & Wonder
LNW
| $813K | ﹤0.01% |
72,156
+1,400
| +2% | +$13.7K |
|
2312
CorVel
CRVL
$3.05B
| $808K | ﹤0.01% |
63,162
-600
| -0.9% | -$8.31K |
|
|
CBPX
2313
DELISTED
CONTINENTAL BUILDING PRODUCTS, INC.
CBPX
| $804K | ﹤0.01% |
38,300
+2,800
| +8% | +$63K |
|
|
FARO
2314
DELISTED
Faro Technologies
FARO
| $799K | ﹤0.01% |
22,232
-200
| -0.9% | -$6.78K |
|
2315
Modine Manufacturing
MOD
$12.8B
| $796K | ﹤0.01% |
67,080
-1,200
| -2% | -$12.5K |
|
2316
CEVA Inc
CEVA
$1.01B
| $794K | ﹤0.01% |
22,650
| – | – |
|
|
BPMC
2317
DELISTED
Blueprint Medicines
BPMC
| $793K | ﹤0.01% |
26,700
+8,600
| +48% | +$214K |
|
2318
TFS Financial
TFSL
$5.1B
| $793K | ﹤0.01% |
44,546
-2,250
| -5% | -$40.4K |
|
|
KERX
2319
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $793K | ﹤0.01% |
149,340
-11,700
| -7% | -$63.1K |
|
2320
Regis Corp
RGS
$69.9M
| $792K | ﹤0.01% |
3,157
-60
| -2% | -$15.7K |
|
|
EXTN
2321
DELISTED
Exterran Corporation
EXTN
| $792K | ﹤0.01% |
50,500
| – | – |
|
2322
National Beverage
FIZZ
$2.87B
| $791K | ﹤0.01% |
35,900
+1,000
| +3% | +$26.9K |
|
2323
First Northwest Bancorp
FNWB
$114M
| $791K | ﹤0.01% |
58,630
-27,989
| -32% | -$369K |
|
|
THR
2324
DELISTED
Thermon Group Holdings
THR
| $788K | ﹤0.01% |
39,920
| – | – |
|
|
ARNA
2325
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $787K | ﹤0.01% |
44,965
| – | – |
|
Similar funds
AllianceBernstein's Q3 2016 Portfolio in Review
As of Q3 2016, AllianceBernstein held 3,058 positions worth $118B, up 2% from $116B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AllianceBernstein's Q3 2016 filing shows 95 new, 1,049 increased, 1,331 reduced and 82 closed positions. Its largest new stake was Teva Pharmaceuticals: 2,294,681 shares worth $106M. The largest sale was Pfizer, an estimated $274M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 15% a quarter earlier, followed by Financials and Healthcare.
- AllianceBernstein's largest Q3 2016 buy was Teva Pharmaceuticals: 2,294,681 shares worth $106M.
- AllianceBernstein added most to State Street SPDR S&P 500 ETF Trust in Q3 2016, an estimated $567M increase.
- AllianceBernstein's biggest Q3 2016 reduction was Pfizer, cutting an estimated $274M.
- AllianceBernstein fully exited EMC CORPORATION in Q3 2016, selling an estimated $99.6M.
- AllianceBernstein's ten largest holdings make up 14% of its $118B portfolio in Q3 2016.
- AllianceBernstein opened 95 new positions and closed 82 in Q3 2016.
- AllianceBernstein's portfolio value rose 2% quarter-over-quarter to $118B.
Based on AllianceBernstein's 13F filing for Q3 2016, filed 10 Nov 2016.